# Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

> **NCT04089904** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 3 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab Injection

## Key facts

- **NCT ID:** NCT04089904
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-11
- **Primary completion:** 2023-03-11
- **Final completion:** 2023-03-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual.
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089904, "Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04089904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*